Core and Main Inc vs Johnson & Johnson — how do they compare? Core and Main Inc trades at $44.98 (market cap $8.46B), while Johnson & Johnson trades at $252.82 (market cap $611.07B). The key difference: Johnson & Johnson is far larger — about 72.2× Core and Main Inc's market cap, and Johnson & Johnson pays a 2.11% dividend while Core and Main Inc pays none. Which is the better fit depends on your goals.
| CNM | JNJ | |
|---|---|---|
Market Cap | $8.46B | $611.07B |
Sector | Technology | Health |
52-Week High | $66.98 | $267.24 |
52-Week Low | $44.29 | $155.17 |
Enterprise Value | $10.76B | $644.01B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.11% |
Signals from Pluang's Aura AI — not financial advice
Core & Main (CNM) trades at $44.74, down 2.44% today, amid bearish technical signals but strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.72 exceeding expectations, and maintains solid profitability with a 23.73% ROE. Recent news highlights municipal strength and margin gains, though residential segments face weakness. Cash flow trends improved in 2026 projections, with net cash flow rising to $142M from $7M in 2025.
The outlook is mixed: analyst consensus leans bullish with 57% buy ratings, but technical indicators signal near-term pressure. Key risks include industry headwinds like high operating costs and residential market softness. Investors should weigh strong fundamentals against current bearish momentum for entry timing.
Johnson & Johnson (JNJ) trades at $257.77, up 0.31% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with 2025 revenue of $94.19B, net income margin of 21.83%, and consistent earnings beats. Recent dividend declaration of $1.34 and positive analyst coverage with 52.5% buy ratings reinforce confidence. The current price sits near pivot point resistance at $258, with technical indicators showing bullish momentum from moving averages.
JNJ presents a compelling long-term investment with stable cash flows, strong profitability metrics, and defensive healthcare positioning. Upside potential exists toward the $281 consensus price target, though risks include rising debt-to-asset ratio (24.06% in 2025) and patent expiration headwinds. The stock's 60+ year dividend growth history provides income stability amid market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →